Literature DB >> 18543251

GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

Shuanzeng Wei1, Thomas A Dunn, William B Isaacs, Angelo M De Marzo, Jun Luo.   

Abstract

BACKGROUND: Malignant transformation is often accompanied by morphological and functional alterations in subcellular organelles. The Golgi apparatus is a subcellular structure primarily involved in modification and sorting of macromolecules for secretion and transport to other cellular destinations. Molecular alterations associated with the Golgi apparatus may take place during prostate carcinogenesis but such alterations have not been documented.
METHODS: To demonstrate that the Golgi apparatus undergoes alterations during prostate carcinogenesis, we examined the expression and localization of two candidate molecules, Golgi phosphoprotein 2 (GOLPH2) and myosin VI (MYO6), both overexpressed in prostate cancer as initially identified by expression microarray analysis.
RESULTS: Elevated GOLPH2 expression in prostate cancers was validated through real-time RT-PCR, Western blot, and tissue microarray analysis, and its Golgi localization in surgical prostate cancer tissues confirmed using two-color immunofluorescence. In addition, distinctive juxtanuclear MYO6 staining pattern consistent with Golgi localization was observed in surgical prostate cancer tissues. Two-color immunofluorescence revealed intensive Golgi-specific staining for both GOLPH2 and myosin VI in prostate cancer cells but not in the adjacent normal prostate epithelium.
CONCLUSIONS: We show that the Golgi apparatus in prostate cancer cells differs from the normal Golgi by elevated levels of two molecules, GOLPH2 and MYO6. These results for the first time demonstrated consistent cancer cell-specific alterations in the molecular composition of the Golgi apparatus. Such alterations can be explored for discovery of novel prostate cancer biomarkers through targeted organellar approaches. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18543251      PMCID: PMC4124602          DOI: 10.1002/pros.20806

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  26 in total

1.  Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption.

Authors:  Sapna Puri; Collin Bachert; Claus J Fimmel; Adam D Linstedt
Journal:  Traffic       Date:  2002-09       Impact factor: 6.215

Review 2.  Cell-cycle-specific Golgi fragmentation: how and why?

Authors:  Antonino Colanzi; Christine Suetterlin; Vivek Malhotra
Journal:  Curr Opin Cell Biol       Date:  2003-08       Impact factor: 8.382

3.  CLASPing microtubules at the trans-Golgi network.

Authors:  Zhonghua Liu; Queenie P Vong; Yixian Zheng
Journal:  Dev Cell       Date:  2007-06       Impact factor: 12.270

4.  Asymmetric CLASP-dependent nucleation of noncentrosomal microtubules at the trans-Golgi network.

Authors:  Andrey Efimov; Alexey Kharitonov; Nadia Efimova; Jadranka Loncarek; Paul M Miller; Natalia Andreyeva; Paul Gleeson; Niels Galjart; Ana R R Maia; Ian X McLeod; John R Yates; Helder Maiato; Alexey Khodjakov; Anna Akhmanova; Irina Kaverina
Journal:  Dev Cell       Date:  2007-06       Impact factor: 12.270

Review 5.  Real-time PCR for mRNA quantitation.

Authors:  Marisa L Wong; Juan F Medrano
Journal:  Biotechniques       Date:  2005-07       Impact factor: 1.993

6.  Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to Disabled-2 and PtdIns(4,5)P2.

Authors:  Giulietta Spudich; Margarita V Chibalina; Josephine Sui-Yan Au; Susan D Arden; Folma Buss; John Kendrick-Jones
Journal:  Nat Cell Biol       Date:  2006-12-24       Impact factor: 28.824

7.  Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in late pathological stage human prostate cancer.

Authors:  R H Rondinelli; D E Epner; J V Tricoli
Journal:  Prostate Cancer Prostatic Dis       Date:  1997-12       Impact factor: 5.554

Review 8.  Nuclear microenvironments in biological control and cancer.

Authors:  Sayyed K Zaidi; Daniel W Young; Amjad Javed; Jitesh Pratap; Martin Montecino; Andre van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

Review 9.  How are the cellular functions of myosin VI regulated within the cell?

Authors:  Folma Buss; John Kendrick-Jones
Journal:  Biochem Biophys Res Commun       Date:  2007-12-07       Impact factor: 3.575

10.  GP73, a novel Golgi-localized protein upregulated by viral infection.

Authors:  R D Kladney; G A Bulla; L Guo; A L Mason; A E Tollefson; D J Simon; Z Koutoubi; C J Fimmel
Journal:  Gene       Date:  2000-05-16       Impact factor: 3.688

View more
  35 in total

1.  Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.

Authors:  Lei Zhang; Rong Hu; Yanyong Cheng; Xiaoyang Wu; Siwei Xi; Yu Sun; Hong Jiang
Journal:  Cell Prolif       Date:  2017-07-24       Impact factor: 6.831

2.  Evaluation of ERG responsive proteome in prostate cancer.

Authors:  Shyh-Han Tan; Bungo Furusato; Xueping Fang; Fang He; Ahmed A Mohamed; Nicholas B Griner; Kaneeka Sood; Sadhvi Saxena; Shilpa Katta; Denise Young; Yongmei Chen; Taduru Sreenath; Gyorgy Petrovics; Albert Dobi; David G McLeod; Isabell A Sesterhenn; Satya Saxena; Shiv Srivastava
Journal:  Prostate       Date:  2013-09-21       Impact factor: 4.104

3.  Contribution of the myosin VI tail domain to processive stepping and intramolecular tension sensing.

Authors:  Alexander R Dunn; Peiying Chuan; Zev Bryant; James A Spudich
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

4.  Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners.

Authors:  Seong Jun Cho; Xinbin Chen
Journal:  J Biol Chem       Date:  2010-06-23       Impact factor: 5.157

5.  Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.

Authors:  Hongyan Liang; Timothy M Block; Mengjun Wang; Bradley Nefsky; Ronald Long; Julie Hafner; Anand S Mehta; Jorge Marrero; Robert Gish; Pamela A Norton
Journal:  Cancer Biomark       Date:  2012       Impact factor: 4.388

6.  Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer.

Authors:  Sooryanarayana Varambally; Bharathi Laxman; Rohit Mehra; Qi Cao; Saravana M Dhanasekaran; Scott A Tomlins; Jill Granger; Adaikkalam Vellaichamy; Arun Sreekumar; Jianjun Yu; Wenjuan Gu; Ronglai Shen; Debashis Ghosh; Lorinda M Wright; Raleigh D Kladney; Rainer Kuefer; Mark A Rubin; Claus J Fimmel; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

7.  Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).

Authors:  Heike Liewen; Norbert Markuly; Heinz Läubli; Yang Liu; Matthias S Matter; Nora Liewen; Christoph Renner; Alfred Zippelius; Frank Stenner
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

8.  GOLPH2 expression may serve as diagnostic marker in seminomas.

Authors:  Florian R Fritzsche; Glen Kristiansen; Marc-Oliver Riener; Manfred Dietel; Beibei Oelrich
Journal:  BMC Urol       Date:  2010-02-25       Impact factor: 2.264

9.  Novel diagnostic biomarkers for prostate cancer.

Authors:  Chikezie O Madu; Yi Lu
Journal:  J Cancer       Date:  2010-10-06       Impact factor: 4.207

10.  Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis.

Authors:  C Puri; M V Chibalina; S D Arden; A J Kruppa; J Kendrick-Jones; F Buss
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.